EP1679069A4 — NEW PIPERIDINE DERIVATIVE
Assigned to Sumitomo Pharma Co Ltd · Expires 2009-05-13 · 17y expired
What this patent protects
A compound represented by the following formula (1), a prodrug thereof, or a pharmaceutically acceptable salt of either. They are effective in enhancing LDL receptor manifestation and are useful as a therapeutic agent for hyperlipemia, arteriosclerosis, etc. (1) (In the formula, …
USPTO Abstract
A compound represented by the following formula (1), a prodrug thereof, or a pharmaceutically acceptable salt of either. They are effective in enhancing LDL receptor manifestation and are useful as a therapeutic agent for hyperlipemia, arteriosclerosis, etc. (1) (In the formula, m, n, and p each independently is an integer of 0 to 4, provided that 3≤m+n≤8; X represents nitrogen or a group represented by C-R15; Y represents an (un)substituted aromatic group; R15, R1, R2, R3, R4, R5, R6, and R7 each represents hydrogen, (un)substituted alkyl, etc.; and Z represents hydrogen, cyano, etc.)
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.